All News

Article

Inflammatory bowel disease in spondyloarthritis - does it matter?

Antoni Chan, MD, PhD Jun 13, 2024

Do the clinical features of axSpA patients with and without IBD differ?

In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in axSpA patients with or without IBD as the emerging therapies have different effects on EMMs.

Article

Humira Clobbers Biosimilars in Battle for Part D Coverage

Medpage Today Jun 10, 2024

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar versions currently approved, researchers found.

Article

Is Cannabis Safe? (6.7.2024)

Jack Cush, MD Jun 07, 2024

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

500+ pts AxSPA No difference in drug discontinuation between IL-17i, TNFi, IL23i over time Adjusted for CRP, co-medication w/ MTX + classic covariates IL-17i and IL-23i had experienced a higher number bDMARD failures #EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca

https://twitter.com/AurelieRheumo/status/1801515410027672008/photo/1

What is the meaning of mechanical stress-induced sacroiliac BMO MRI after childbirth in healthy women? 5yrs follow up MRI study shows: -decrease in BMO -1/3 BMO @ 5-year follow-up -15% ASAS definition of sacroiliitis -No correlation w/ symptoms @RheumNow #EULAR24 OP0222

EFFECTIVENESS & COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPA (TeleSpA-STUDY): PRAGMATIC MULTICENTRE RVT cost effective but no one will ever be examined again especially for pathology outside joints! @rheumnow #EULAR2024

beautiful work Univ of Qld - rat SpA model bacterial dna into entheses blocked by 23i not 17i @RheumNow #EULAR2024 https://t.co/X9hzkA56d0

https://twitter.com/drpnash/status/1801547448709414948/photo/1

Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9

#Editors Picks @eular_org @ARD_BMJ @ACR_Journals Can #rheumatologists effectively #dx of #ankylosing #spondylitis? 👍 552 pts - 1/3 axSpA w high certainty Certainty of #dx changed over time 2 features #sacroileitis good #nSAID response #EULAR2024 @RheumNow https://t.co/NN3GZTmgn9

10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.… https://t.co/HrRnoDzSPP https://t.co/Gp1KZmPych

Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn

https://twitter.com/synovialjoints/status/1800920604838924393/photo/1

Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independently associated with greater radiographic progression #EULAR2024 OP0103 @RheumNow https://t.co/j7UblASUvC

SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085 @RheumNow https://t.co/c2KdzIumc4

https://twitter.com/synovialjoints/status/1800918388690108811/photo/1

Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024 @RheumNow https://t.co/vr5DvNOb21

https://twitter.com/synovialjoints/status/1800915408175927352/photo/1

Treatment intensification is associated with a higher ASDAS cut-off value than the recommended one (≥2.1). Rheumatologists may feel this is too stringent and use a higher ASDAS value for treatment intensification #EULAR2024 Abstract 0060 @RheumNow https://t.co/54vZUz7IEz

https://twitter.com/synovialjoints/status/1800913941041967564/photo/1

In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/wMasGSZj2o

💊 Difficult-to-treat #SpA & #PsA 🤔 What are the challenges in assessing persistently active disease? 🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease 🌎 Great to see #comorbidities highlighted @RheumNow #EULAR2024 https://t.co/x4jUTOC3li

Consider the source and type of pain when managing axSpA including nociplastic pain. Difficult to treat axSpA #EULAR2024 Rudwaleit M @RheumNow https://t.co/4rszIyw5V6

Ankylosing spondylitis Tx w/ Tofa- How quick do they respond? Post hoc analysis 269 pts: - 4 wks for Pain >30% - 4 wks for ASDAS improved ≥ 1.1 points - 8-24 wks for ≥ 50% improved pain, enthesitis, AM stiffness, BASDAI & fatigue https://t.co/YOZgRLfPNc https://t.co/egkG76gz2E https://t.co/ZknXhKE0N4

Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg

https://buff.ly/3yS7cIw

Topics

All News

Inflammatory bowel disease in spondyloarthritis - does it matter?

Humira Clobbers Biosimilars in Battle for Part D Coverage

Is Cannabis Safe? (6.7.2024)

Do you get our email newsletter?